Two new weapons in the battle against bacteria

But proteases are important not only for human cells -- bacteria also rely on them. There are hardly any effective antibiotics left in the fight against pathogens like multi-resistant strains of Staphylococcus aureus bacteria or Mycobacterium tuberculosis which causes tuberculosis.

Researchers around the world are thus working ardently to find new ways of disarming the proteases in these strains to combat them. At the heart of this effort lies the so-called ClpP protease. It comprises 14 subunits and has a central regulatory function. The usual approach to deactivating this protease is to block all active centers of the ClpP. These are effectively the "cutting edges of the scissors," i.e. the portions of the protein that are responsible for breaking apart other proteins.

"However, the inhibitors used in the past have one decisive disadvantage," explains Stephan Sieber who heads the Chair for Organic Chemistry II at the Technische Universitaet Muenchen (TUM). "They don't permanently disarm the proteins, but only work for a few hours. On top of that, to be effective they must attack all active centers of the protein."

New strategies against bacteria

In collaboration with Professor Michael Groll, who heads the Chair for Biochemistry, Malte Gersch and Roman Kolb, doctoral candidates at Professor Sieber's chair, have succeeded in uncovering two completely new mechanisms that can be used to permanently deactivate these important bacteriological proteases -- in one case even without having to attack all active centers of the protein.

The first mechanism disrupts the arrangement of amino acids required for the cohesion of the protease subunits. As a result the protease breaks into two parts. The second acts directly on the core of the active center. It converts the amino acid that does the actual splitting into another kind of amino acid -- the "scissors" lose their edge and the protein is rendered inoperable. Both approaches inhibit the protease in completely novel ways and are thus very promising for the development of new forms of medication.

The scientists also found a whole series of inhibitors that initiate the two mechanisms. "Knowing the ways in which substances deactivate the proteases is a huge advance," says Gersch. "We can now optimize the substances and possibly also apply the principle to other proteases."

In further research, Gersch and Sieber plan to test their substances on living bacterial strains to determine if these are truly inhibited in growth and pathogenic effect. "Although the bacteria are not completely disarmed, they produce significantly fewer toxins that are conducive to inflammation," says Gersch. "The basic idea is that we give the immune system more time to handle the pathogens on its own while the formation of new resistances is suppressed."